ALNYLAM PHARMACEUTICALS, INC. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $1.05 billion as of 2019-03-31, per its 10-Q filed 2019-05-02.
Discontinued › Notes › Investments › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2019-05-02
- 2019-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $1.05B.
- 2018-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $662.80M.
- 2018-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $905.22M.
- 2018-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $1.07B.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2019-03-31 | $1.05B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $662.80M 10-K · filed 2019-02-14 |
| 2018-09-30 | $905.22M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.07B 10-Q · filed 2018-08-02 |
| 2018-03-31 | $1.17B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $1.05B 10-K · filed 2018-02-15 |
| 2017-09-30 | $746.25M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $514.60M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $385.84M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $424.19M 10-K · filed 2017-02-15 |
| 2016-09-30 | $531.04M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $571.99M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $748.42M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $848.22M 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |